New Research Released on CEL-SCI Corporation (CVM-NYSE)

Posted by Karen Goldfarb

June 3, 2020 at 12:34 PM

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download CEL-SCI Corporation Report

Read More

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic